The incidence and risk factors of selected drug prescriptions and outpatient care after SARS-CoV-2 infection in low-risk subjects: a multicenter population-based cohort study.
COVID-19 sequelae
ORCHESTRA project
SARS-CoV-2
drug prescriptions
low-risk subjects
outpatient care
population-based cohort
post-COVID
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
06
2023
accepted:
20
09
2023
medline:
23
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
Knowledge about the dynamics of transmission of SARS-CoV-2 and the clinical aspects of COVID-19 has steadily increased over time, although evidence of the determinants of disease severity and duration is still limited and mainly focused on older adult and fragile populations. The present study was conceived and carried out in the Emilia-Romagna (E-R) and Veneto Regions, Italy, within the context of the EU's Horizon 2020 research project called ORCHESTRA (Connecting European Cohorts to increase common and effective response to SARS-CoV-2 pandemic) (www.orchestra-cohort.eu). The study has a multicenter retrospective population-based cohort design and aimed to investigate the incidence and risk factors of access to specific healthcare services (outpatient visits and diagnostics, drug prescriptions) during the post-acute phase from day-31 to day-365 after SARS-CoV-2 infection, in a healthy population at low risk of severe acute COVID-19. The study made use of previously recorded large-scale healthcare data available in the administrative databases of the two Italian Regions. The statistical analysis made use of methods for competing risks. Risk factors were assessed separately in the two Regions and results were pooled using random effects meta-analysis. There were 35,128 subjects in E-R and 88,881 in Veneto who were included in the data analysis. The outcome (access to selected health services) occurred in a high percentage of subjects in the post-acute phase (25% in E-R and 21% in Veneto). Outpatient care was observed more frequently than drug prescriptions (18% vs. 12% in E-R and 15% vs. 10% in Veneto). Risk factors associated with the outcome were female sex, age greater than 40 years, baseline risk of hospitalization and death, moderate to severe acute COVID-19, and acute extrapulmonary complications. The outcome of interest may be considered as a proxy for long-term effects of COVID-19 needing clinical attention. Our data suggest that this outcome occurs in a substantial percentage of cases, even among a previously healthy population with low or mild severity of acute COVID-19. The study results provide useful insights into planning COVID-19-related services.
Sections du résumé
Background
Knowledge about the dynamics of transmission of SARS-CoV-2 and the clinical aspects of COVID-19 has steadily increased over time, although evidence of the determinants of disease severity and duration is still limited and mainly focused on older adult and fragile populations.
Methods
The present study was conceived and carried out in the Emilia-Romagna (E-R) and Veneto Regions, Italy, within the context of the EU's Horizon 2020 research project called ORCHESTRA (Connecting European Cohorts to increase common and effective response to SARS-CoV-2 pandemic) (www.orchestra-cohort.eu). The study has a multicenter retrospective population-based cohort design and aimed to investigate the incidence and risk factors of access to specific healthcare services (outpatient visits and diagnostics, drug prescriptions) during the post-acute phase from day-31 to day-365 after SARS-CoV-2 infection, in a healthy population at low risk of severe acute COVID-19. The study made use of previously recorded large-scale healthcare data available in the administrative databases of the two Italian Regions. The statistical analysis made use of methods for competing risks. Risk factors were assessed separately in the two Regions and results were pooled using random effects meta-analysis.
Results
There were 35,128 subjects in E-R and 88,881 in Veneto who were included in the data analysis. The outcome (access to selected health services) occurred in a high percentage of subjects in the post-acute phase (25% in E-R and 21% in Veneto). Outpatient care was observed more frequently than drug prescriptions (18% vs. 12% in E-R and 15% vs. 10% in Veneto). Risk factors associated with the outcome were female sex, age greater than 40 years, baseline risk of hospitalization and death, moderate to severe acute COVID-19, and acute extrapulmonary complications.
Conclusion
The outcome of interest may be considered as a proxy for long-term effects of COVID-19 needing clinical attention. Our data suggest that this outcome occurs in a substantial percentage of cases, even among a previously healthy population with low or mild severity of acute COVID-19. The study results provide useful insights into planning COVID-19-related services.
Identifiants
pubmed: 37860802
doi: 10.3389/fpubh.2023.1241401
pmc: PMC10582710
doi:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241401Informations de copyright
Copyright © 2023 Gagliotti, Banchelli, De Paoli, Buttazzi, Narne, Ricchizzi, Schievano, Bellio, Pitter, Tonon, Canziani, Rolli, Tacconelli, Berti, Russo and Moro.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):515-545
pubmed: 35142947
Intern Emerg Med. 2023 Apr;18(3):801-809
pubmed: 36944811
Infect Dis (Lond). 2022 Jul;54(7):467-477
pubmed: 35282780
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Open Forum Infect Dis. 2020 Oct 21;7(12):ofaa509
pubmed: 33403218
Lancet Respir Med. 2022 Sep;10(9):863-876
pubmed: 35568052
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
Lancet Reg Health Eur. 2021 Jul;6:100122
pubmed: 34027514
Open Forum Infect Dis. 2021 Sep 09;8(10):ofab440
pubmed: 34631916
BMC Med. 2023 Feb 16;21(1):58
pubmed: 36793086
Lancet Respir Med. 2021 Dec;9(12):1467-1478
pubmed: 34416191
Public Health Rev. 2022 Mar 15;43:1604501
pubmed: 35359614
Lancet Diabetes Endocrinol. 2022 May;10(5):311-321
pubmed: 35325624
Pathogens. 2022 Feb 19;11(2):
pubmed: 35215212
J Clin Med. 2021 Dec 16;10(24):
pubmed: 34945213
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
Lancet Planet Health. 2020 Aug;4(8):e312-e314
pubmed: 32702296
BMJ Open. 2014 Sep 17;4(9):e005223
pubmed: 25231488
Eur J Intern Med. 2020 Jul;77:161-162
pubmed: 32527610
Nat Rev Microbiol. 2023 Mar;21(3):133-146
pubmed: 36639608
Front Med (Lausanne). 2023 Apr 20;10:1168628
pubmed: 37153089